FIGURE 8.

Treatment with RSK inhibitor FMK-MEA significantly attenuates activation of RSK2-CREB-Fascin-1 pathway in metastatic cells in vivo. A–C, IHC staining of phospho-RSK2 Ser-386 (A), phospho-CREB Ser-133 (B), and Fascin-1 (C) using LN samples from M4e xenograft nude mice treated with PBS or FMK-MEA. Representative IHC staining images for each group are shown on the left. Expression was characterized by weighted index (WI = positive staining (%) × intensity score (0∼3+)). p values were determined by Student's t test. D, Western blot results show a decrease of RSK2 and CREB activity as well as Fascin-1 expression upon FMK-MEA treatment in total tumor lysates.